Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIIA

Condition:   Non Small Cell Lung Cancer Interventions:   Drug: anti-PD-1 or anti-PD-L1;   Drug: EGFR-TKI, ALK inhibitor, ROS1 inhibitor;   Drug: investigator decided Sponsor:   Shanghai Chest Hospital Recruiting

Source: ClinicalTrials.gov - December 12, 2019 Category: Research Source Type: clinical trials